Novartis raised its 2024 earnings guidance for the third time on Tuesday, buoyed by wider use of its prescription drugs, but ...

A suit against Novartis and Vitaris by Henrietta Lacks’ estate hinges on questions about the morality and legality of using ...

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its ...

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the third quarter of 2024. Core earnings ...

Not long after Basel, Switzerland, was selected as the next host of the annual Eurovision Song Contest, hometown pharma ...

Novartis AG is a Swiss multinational pharmaceutical corporation with its headquarters in Basel, it is one of the largest ...

Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...

C3G is estimated to affect around one person per million in the US, a small patient population, but is one of a series of ...

Novartis has received FDA accelerated approval for Scemblix (asciminib) to treat adults with newly diagnosed Ph+ CML-CP.

A new survey shows that three Big Pharmas have stolen the hearts of patient groups representing nearly 1 million people with cardiovascular conditions. | A new survey shows that three Big Pharmas have ...

The EMA has accepted a MAA for Alvotech and Advanz Pharma’s AVT05, a proposed biosimilar to Johnson & Johnson’s (J&J) Simponi ...